The cortical silent period in schizophrenia: A systematic review and meta-analysis focusing on disease stage and antipsychotic medication
- 27 April 2022
- journal article
- review article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 36 (4) , 479-488
Abstract
Background: Although numerous studies reported some changes of cortical silent period (CSP), an indicator of gamma-aminobutyric acid (GABA) function in central nervous system, in schizophrenia patients, it has been unknown how the disease stage and antipsychotic medication affect CSP values. Methods: The present study conducted a systematic review of previous literature comparing CSP between schizophrenia patients and healthy subjects, and then performed meta-analysis on the effects of (1) the disease stage and (2) antipsychotics on CSP. Results: (1) In the comparison of the disease stage comprising a total of 17 reports, there was no significant difference in CSP between patients under drug-naïve first-episode psychoses and healthy controls, or between patients with antipsychotic medication and healthy controls. (2) In the comparison of the antipsychotic class, patients treated with clozapine were longer in CSP compared to healthy controls. Patients treated with olanzapine/quetiapine or with other type of antipsychotics were not different from healthy controls. Regarding other type of antipsychotics, the iteration analysis after leaving out one literature showed that patients were shorter in CSP than healthy controls. Conclusion: The results showed that clozapine seems to surely prolong CSP, indicating the enhancement of GABA transmission via GABAB receptors, suggesting the possible relationship between the CSP prolongation by clozapine and its high efficacy in psychopathology. The finding of shorter CSP in patients with other type of antipsychotics was distinct from clozapine/olanzapine/quetiapine, but was difficult to interpret since this group included a variety of transcranial magnetic stimulation (TMS) methodologies and patients’ background.Keywords
Funding Information
- Japan Society for the Promotion of Science (Grand-in-Aid for Scientific Research/21K07476)
This publication has 68 references indexed in Scilit:
- Disrupted Central Inhibition after Transcranial Magnetic Stimulation of Motor Cortex in Schizophrenia with Long-Term Antipsychotic TreatmentISRN Psychiatry, 2013
- Impaired long-term depression in schizophrenia: A cathodal tDCS pilot studyBrain Stimulation, 2012
- Glutamate Neurocircuitry: Theoretical Underpinnings in SchizophreniaFrontiers in Pharmacology, 2012
- Cortical parvalbumin interneurons and cognitive dysfunction in schizophreniaTrends in Neurosciences, 2012
- Hippocampal interneurons are abnormal in schizophreniaSchizophrenia Research, 2011
- Cortical Deficits of Glutamic Acid Decarboxylase 67 Expression in Schizophrenia: Clinical, Protein, and Cell Type-Specific FeaturesAmerican Journal of Psychiatry, 2011
- Driving fast-spiking cells induces gamma rhythm and controls sensory responsesNature, 2009
- Subunit-Selective Modulation of GABA Type A Receptor Neurotransmission and Cognition in SchizophreniaAmerican Journal of Psychiatry, 2008
- Motor threshold in transcranial magnetic stimulation: The impact of white matter fiber orientation and skull‐to‐cortex distanceHuman Brain Mapping, 2008
- GABA Neurons and the Mechanisms of Network Oscillations: Implications for Understanding Cortical Dysfunction in SchizophreniaSchizophrenia Bulletin, 2008